STOCK TITAN

Lexicon (NASDAQ: LXRX) director converts 89,312 RSUs into common stock, boosts stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LEXICON PHARMACEUTICALS, INC. director Raymond Debbane exercised restricted stock units into common stock. He converted 89,312 restricted stock units at an exercise price of $0.00 per unit into 89,312 shares of common stock and now holds 1,995,498 shares directly. Entities associated with him hold additional indirect positions of 35,402,689, 5,451,204, 7,362,368 and 1,538,462 common shares as of the reported date.

Positive

  • None.

Negative

  • None.
Insider DEBBANE RAYMOND
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 89,312 $0.00 --
Exercise Common Stock 89,312 $0.00 --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 1,995,498 shares (Direct, null); Common Stock — 1,538,462 shares (Indirect, By Avicenna Life Sci Master Fund LP and related parties)
Footnotes (1)
  1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock.
RSUs exercised 89,312 units Restricted stock units converted to common stock on transaction date
Exercise price $0.00 per unit Conversion price for 89,312 restricted stock units
Direct shares after transaction 1,995,498 shares Common stock directly held by Raymond Debbane after RSU conversion
Indirect Invus, L.P. holding 35,402,689 shares Common stock held indirectly via Invus, L.P. and related parties
Indirect Invus US Partners holding 5,451,204 shares Common stock held indirectly via Invus US Partners, LLC
Indirect Invus Public Equities holding 7,362,368 shares Common stock held indirectly via Invus Public Equities, L.P.
Indirect Avicenna Life Sci holding 1,538,462 shares Common stock held indirectly via Avicenna Life Sci Master Fund LP
Restricted Stock Units financial
"The security title is listed as "Restricted Stock Units" for the derivative entry."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"The transaction code description notes an "Exercise or conversion of derivative security"."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
indirect ownership financial
"Ownership type is marked as indirect for holdings via Invus, L.P. and related parties."
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share of common stock."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DEBBANE RAYMOND

(Last)(First)(Middle)
2445 TECHNOLOGY FOREST BLVD.
11TH FLOOR

(Street)
THE WOODLANDS TEXAS 77381

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/03/2026M89,312A$01,995,498D
Common Stock1,538,462IBy Avicenna Life Sci Master Fund LP and related parties
Common Stock7,362,368IBy Invus Public Equities, L.P. and related parties
Common Stock5,451,204IBy Invus US Partners, LLC and related parties
Common Stock35,402,689IBy Invus, L.P. and related parties
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$006/03/2026M89,312 (1) (2)Common Stock89,312$00D
Explanation of Responses:
1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
2. Each restricted stock unit represents a contingent right to receive one share of common stock.
/s/ Raymond Debbane06/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Raymond Debbane report at Lexicon Pharmaceuticals (LXRX)?

Raymond Debbane reported exercising 89,312 restricted stock units into common stock. The units converted on a one-for-one basis into 89,312 Lexicon Pharmaceuticals shares at an exercise price of $0.00 per unit, reflecting the vesting of previously granted equity compensation.

How many Lexicon Pharmaceuticals (LXRX) shares does Raymond Debbane hold directly after this Form 4?

After the reported transaction, Raymond Debbane holds 1,995,498 Lexicon Pharmaceuticals common shares directly. This figure reflects his direct ownership following the exercise and conversion of 89,312 restricted stock units into common stock on the reported transaction date.

What indirect Lexicon Pharmaceuticals (LXRX) holdings are associated with Raymond Debbane?

Entities associated with Raymond Debbane report indirect ownership of Lexicon shares, including 35,402,689 shares via Invus, L.P., 5,451,204 via Invus US Partners, LLC, 7,362,368 via Invus Public Equities, L.P., and 1,538,462 via Avicenna Life Sci Master Fund LP, as of the transaction date.

What are the terms of the restricted stock units reported by Raymond Debbane at LXRX?

Each restricted stock unit represents a contingent right to receive one Lexicon common share. The unit award vests with respect to 100% of the shares subject to the grant on the first anniversary of the grant date, then converts into common stock upon vesting.

Does the Form 4 for Raymond Debbane at LXRX show any stock sales?

The Form 4 shows an exercise of restricted stock units but no reported stock sales. The primary reportable event is the conversion of 89,312 restricted stock units into 89,312 common shares, increasing his direct equity holdings in Lexicon Pharmaceuticals.